---
title: "Jefferies Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292338596.md"
description: "Jefferies analyst Dennis Ding maintained a Buy rating on Teva Pharmaceutical (TEVA) with a $40 price target. This follows Bank of America Securities reiterating a Buy rating and the same $40 target for the stock. The report highlights Ding's strong performance as a 4-star analyst in the Healthcare sector."
datetime: "2026-07-10T14:05:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292338596.md)
  - [en](https://longbridge.com/en/news/292338596.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292338596.md)
generator: "portal-rs"
---

# Jefferies Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)

In a report released today, Dennis Ding from Jefferies maintained a Buy rating on Teva Pharmaceutical, with a price target of $40.00.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

According to TipRanks, Ding is a 4-star analyst with an average return of 12.7% and a 56.79% success rate. Ding covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Rhythm Pharmaceuticals, and Esperion.

In a report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $40.00 price target.

### Related Stocks

- [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)
- [RYTM.US](https://longbridge.com/en/quote/RYTM.US.md)
- [ESPR.US](https://longbridge.com/en/quote/ESPR.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [Ecopipam Priority Review Could Be A Game Changer For Teva Pharmaceutical Industries (TEVA)](https://longbridge.com/en/news/296688992.md)
- [FDA accepts Teva ecopipam NDA for pediatric Tourette syndrome, grants priority review](https://longbridge.com/en/news/296355997.md)
- [Jefferies Sticks to Their Buy Rating for Abbott Laboratories (ABT)](https://longbridge.com/en/news/296645903.md)
- [Jefferies Sticks to Its Buy Rating for Covista (CVSA)](https://longbridge.com/en/news/296118987.md)
- [Teva EVP Business Development Evan Lippman sells 18,600 shares for $680,291.28](https://longbridge.com/en/news/296394259.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**